Don't miss our top 5 cancer-related stories this month, including a guest commentary from an industry leader, our two-part series on trends in cancer research and more!
By E. Kevin Hrusovsky, PerkinElmer Inc.
As the complexity and volume of data continue to rise, bioinformatics is emerging as one of the cornerstones of personalized medicine, from enabling discovery and development of novel treatments and diagnostics to facilitating collection, analysis and interpretation of data that ultimately helps an individual patient.
By Randall Willis, ddn Features Editor
Aiming beyond the standard of care in oncology
By Randall Willis, ddn Features Editor
Are we really making things better for cancer patients?
By Jim Cirigliano, ddn Contributing Editor
Araxes Pharma and Janssen Biotech ink oncology drug development deal
By Kelsey Kaustinen, ddnFeatures Editor
OSU, Biosortia link up to identify natural products for potential cancer treatments
GDBP gains license to monoclonal antibody for China
April 2012

GANSU, China—Privately held Apexigen and Gansu Duyiwei Biological Pharmaceutical (GDBP) have announced a collaboration that will provide GDBP with an exclusive license to develop and commercialize APX004 in China. APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases. Under the agreement, GDBP will be solely responsible for researching, developing and commercializing APX004 in China, while Apexigen will collaborate with GDBP to advance the development program and will retain all rights to the compound outside of China. Apexigen will receive an upfront payment, regulatory milestone payments and a royalty, though no specific financial details were disclosed. Zhiping Duan, CEO of GDBP, said the deal will become a developmental milestone for the company.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.